Comments
Pharma major Lupin Ltd has received an Establishment Inspection Report (EIR) after closure of the US FDA inspection of its Nagpur facility. The inspection for the facility was carried out between January 6 and January 10, 2020.
“We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites,” Nilesh Gupta, Managing Director, Lupin said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.